If you feel like depressing yourself today, check out this blog post from Derek Lowe at In the Pipeline. Lowe points to an analysis performed on a clinical trial for gabapentin (marketed by Pfizer under the name Neurontin) in the '90s. "The authors find, by analyzing a large trove of documents released during lawsuit discovery proceedings, that [the clinical trial] was not really intended to be a clinical trial. Instead, it was a marketing program," Lowe writes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.